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Background: Axillary lymph node dissection (ALND) is important for improving the prognosis of patients with
node-positive breast cancer. However, ALND can be avoided in select micrometastatic cases, preventing complications
such as lymphedema or paresthesia of the upper limb. To appropriately omit ALND from treatment, evaluation of the
axillary tumor burden is critical. The present study evaluated a method for preoperative quantification of axillary lymph
node metastasis using positron emission tomography/computed tomography (PET/CT).
Methods: The records of breast cancer patients who received radical surgery at the Gifu University Hospital (Gifu,
Japan) between 2009 and 2014 were reviewed. The axillary lymph nodes were preoperatively evaluated by PET/CT.
Lymph nodes were dissected by sentinel lymph node biopsy (SLNB) or ALND and were histologically diagnosed by
experienced pathologists. The maximum standardized uptake value (SUVmax) was measured in both the axillary lymph
node (SUV-LN) and primary tumor (SUV-T). The SUV-LN/T ratio (NT ratio) was calculated by dividing the SUV-LN by the
SUV-T, and the efficacies of the NT ratio and SUV-LN were compared using receiver operating characteristic (ROC) curve
analysis. The diagnostic performance was also compared between the techniques with the McNemar test.
Results: A total of 171 operable invasive breast cancer patients were enrolled, comprising 69 node-positive patients
(macrometastasis (Mac): n = 55; micrometastasis (Mic): n = 14) and 102 node-negative patients (Neg). The NT ratio for
node-positive patients was significantly higher than in node-negative patients (0.5 vs. 0.316, respectively, P = 0.041).
The NT ratio for Mac patients (0.571) was significantly higher than in Mic (0.227) and Neg (0.316) patients (P <0.01
and P = 0.021, respectively). The areas under the curves (AUCs) by ROC analysis for the NT ratio and SUV-LN were
0.647 and 0.811, respectively (P <0.01). In patients with an SUV-T ≥2.5, the modified AUCs for the NT ratio and
SUV-LV were 0.757 and 0.797 (not significant).
Conclusion: The NT ratio and SUV-LN are significantly higher in patients with axillary macrometastasis than in
those with micrometastasis or no metastasis. The NT ratio and SUV-LN can help quantify axillary lymph node
metastasis and may assist in macrometastasis identification, particularly in patients with an SUV-T ≥2.5.
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Axillary lymph node metastasis (ALNM) is an important
prognostic factor for invasive breast cancer, and axillary
lymph node dissection (ALND) may improve patient
survival and decrease local recurrence [1,2]. Thus,
ALND should be performed in patients with macrome-
tastasis (Mac), as they have a poorer prognosis than pa-
tients with micrometastasis (Mic). Over half of patients
with Mac develop non-sentinel lymph node (SLN) me-
tastasis [3-6]; thus, the number of metastatic lymph
nodes is critical in therapeutic planning, including
chemo-endocrine therapy, surgery, and radiation ther-
apy. ALND is important for disease control and breast
cancer staging, but it may cause numerous complica-
tions such as lymph edema and sensory or motor distur-
bances in the upper limb. To precisely diagnose ALNM
and perform minimally invasive ALND for breast cancer,
sentinel lymph node biopsy (SLNB) is recommended in
clinically node-negative (Neg) cases because it offers the
same prognosis as ALND [7]. If the SLNB is positive,
then ALND is required.
Even with additional irradiation or chemo-endocrine
therapy, ALND does not improve the prognosis of pa-
tients with Mac [8,9]. In contrast, a minimally invasive
procedure such as SLNB has fewer complications com-
pared to ALND and is therefore commonly performed
in clinically node-negative breast cancer patients. As in-
dicated by the superior clinical outcomes in several clin-
ical trials including the ACOSOG Z0011, IBCSG 23–01,
and AATRM 048/13/2000 trials, small metastatic lesions
that include Mic may not require additional ALND
[9-11]. Thus, as therapy improves, ALND may be
deemed unnecessary for select patients. To accomplish
this goal, axillary evaluation is critical. ALND and
SLNB provide postoperative clinical staging; therefore,
preoperative diagnostic findings should be fully assessed
in breast cancer patients. Ultrasonography (US), com-
puted tomography (CT), and magnetic resonance imaging
(MRI) are common diagnostic modalities, with sensitiv-
ities of 72% to 78%, 78%, and 67%, and specificities of 77%
to 78%, 75%, and 78%, respectively [12-14]. Given their
modest sensitivities and specificities, additional diagnostic
tests are necessary as the diagnostic utility of these mo-
dalities is insufficient.
Recent therapeutic trends suggest that the tumor bur-
den within axillary lymph nodes may impact surgical
planning and prognosis; therefore, quantitative axillary
assessment may be required to discriminate macrome-
tastasis (Mac) from micrometastasis (Mic) and node-
negative (Neg) cases. Common diagnostic modalities
such as MRI, CT, and US can morphologically identify
the metastatic lymph node, but quantification of the
tumor burden and metastasis is difficult. Several methods
of metastatic prediction have been described. Amongthem, nomogram is one representative predictive model
used to identify sentinel or additional lymph node me-
tastasis at several facilities. Nomogram is performed
preoperatively and is based on clinicopathological data,
including age, tumor size, location, lymphovascular in-
vasion, and hormonal receptor activity in biopsy sam-
ples. However, the accuracy of nomogram is limited
according to previous reports, with an area under the
curve (AUC) in the range of 0.688 to 0.721 [15,16]. Re-
cently, two methods of intraoperative detection were
reported. The first, one-step nucleic acid amplification
(OSNA), is a unique quantitative method that amplifies
cytokeratin 19 messenger ribonucleic acid (mRNA).
This method has quickly become widespread because it
produces results similar to those of histopathologic
staining with a >77.5% sensitivity and >95.8% specifi-
city, and provides easy quantitative prediction [17,18].
The second technique, rapid double staining method
with hematoxylin & eosin (HE) stain and immunohisto-
chemistry, has decreased the false negative rate from
33.3% to 16.7% even in patients with Mic [19]. These
methods can be useful in facilities possessing the re-
quired specialized equipment and pathology expertise,
but also require greater concentration to perform due
to time constraints.
In breast cancer medicine, fluorodeoxyglucose positron
emission tomography/computed tomography (FDG-PET/
CT) may be an acceptable alternative for detecting dis-
tant metastases [20,21]. In ALNM evaluation of breast
cancer patients, PET/CT is less sensitive (20% to 37%)
but more specific (>95%) than other modalities [22-25].
It also functionally detects abnormal glucose metabol-
ism; a high maximum standard uptake value (SUVmax)
indicates tumor activity within the axillary lymph node.
For staging and estimating prognosis, the SUV Lymph
node/tumor ratio (NT ratio), defined as the SUVmax
ratio between the axillary lymph node (SUV-LN) and
the primary tumor (SUV-T), is useful in detecting
nodal malignancy in patients with non-small cell lung
cancer [26].
Recent clinical trends indicate that additional lymph-
adenectomy is not required in patients with micrometas-
tasis in the axillary lymph nodes; therefore, preoperative
quantification of axillary disease is required to discrimin-
ate Mac from Mic and Neg. The present study investi-
gates the utility of the NT ratio and SUV-LN as assessed
by PET/CT for quantifying axillary lymph node metasta-
sis in patients with invasive breast cancer.
Methods
Patients
ALNM was evaluated preoperatively using both PET/CT
and conventional CT from June 2009 to February 2014
at Gifu University Hospital (Gifu, Japan). A total of 171
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conserving surgery (BCS) or mastectomy with either
ALND or SLNB were enrolled in this retrospective
study. Patients who were treated by neoadjuvant chemo-
therapy (NAC) and were pathologically diagnosed with
positive lymph nodes by either biopsy or ALND were in-
cluded. The dissected lymph nodes were histologically
diagnosed by experienced pathologists. This study was
approved by the Institutional Ethical Committee, and in-
formed consent was obtained from all patients before
their study inclusion.
PET/CT and NT ratio
Whole body PET/CT (Biograph Sensation 16, Siemens
Medical Solutions, Malvern, PA, USA) was performed
within 1 month before treatment. All patients fasted at
least 4 h prior to the PET/CT procedure. After the
serum glucose concentration was confirmed as <150
mg/dL, patients were administered 185 MBq of 18F-
FDG intravenously in the arm or leg contralateral to the
primary breast tumor and rested quietly for 60 min be-
fore undergoing whole-body PET. CT was performed
immediately after PET, and the PET/CT images were
reconstructed. Two radiologists independently inter-
preted the PET/CT data. The FDG uptake in the pri-
mary tumor (SUV-T) and lymph node (SUV-LN) was
semi-quantitatively analyzed using the SUVmax, which
was calculated based on the measured activity, decay-
corrected administrated dose, and patient weight. When
calculating the SUV-LN, the axillary lymph node show-
ing the highest SUV within the whole axillary space
was selected. The NT ratio was calculated by dividing
the SUV-LN by the SUV-T [26].
Sentinel lymph node biopsy and axillary lymph node
dissection
Each patient underwent either mastectomy or BCS
based on the location and extension of the primary
tumor. ALND was performed in patients with clinically
positive axillary lymph nodes, while in clinically node-
negative patients, SLNB was used for axillary evaluation
[7]. At our institution, SLNB was performed using a
dual-tracer technique, which is a combination of the
blue dye method and the gamma probe-guided (RI)
method. Imaging was performed 1 day preoperatively.
Patients with PET/CT-positive axillae or pathologically
SLNB-positive nodes underwent ALND.
Pathological examination
The dissected sentinel lymph nodes were large enough
for sectioning. The nodes were completely frozen intra-
operatively or fixed in 10% formalin, and then embedded
in paraffin and sectioned at 2-mm intervals. The lymph
nodes that were excised by ALND were sectioned at themaximum diameter. Lesions were independently diag-
nosed as Mac (diameter >2 mm), Mic (0.2 mm < diam-
eter ≤2.0 mm), isolated tumor cell (ITC; diameter ≤0.2
mm) [27,28], or no metastasis by two experienced pa-
thologists based on microscopic examination of the HE
stained sections. ITCs were categorized into the no me-
tastasis group because ITC is considered clinically node-
negative.
Statistical analysis
All statistical analyses were performed using StatFlex
version 6 (Osaka, Japan). Results presented as frequen-
cies or percentages were analyzed as the mean ± stand-
ard deviation (SD). The NT ratio and SUV-LN results
were compared by the Student’s t test. The sensitivity,
specificity, positive predictive value (PPV), negative pre-
dictive value (NPV), and accuracy were estimated using
the appropriate proportions, and the 95% confident in-
tervals (CIs) were calculated using the Wilson score
method [29]. Receiver operating characteristic (ROC)
analysis was performed to determine the diagnostic util-
ity of the NT ratio and SUV-LN in all enrolled patients
and in those with an SUV-T ≥2.5. The diagnostic per-
formance was evaluated using the McNemar test [30].
Results
Patient characteristics
The characteristics of the enrolled patients are detailed
in Table 1. The mean age was 59.2 years, and the mean
tumor size was 20.8 mm. Patients were staged as follows:
Stage I disease: n = 60 (35.1%); Stage IIA: n = 60 (35.1%);
Stage IIB: n = 34 (19.9%); Stage IIIA: n = 7 (4.1%); Stage
IIIB: n = 5 (2.9%); and Stage IIIC: n = 3 (1.7%). Two pa-
tients were not staged because the invasive tumor tissue
was lost during the diagnostic biopsy; these two lesions
each measured approximately 20 mm maximally. The
tumors were histologically graded as follows: grade I,
n = 60 (35.1%); grade II, n = 40 (23.4%); and grade III,
n = 69 (40.3%). Lymph node metastasis was verified
using SLNB in 101 patients (59.1%) and ALND in 70 pa-
tients (40.9%). Histopathological evaluation was as fol-
lows: Mac, 55 patients (32.2%); Mic, 14 patients (8.2%);
ITC, 5 patients (2.9%); and negative metastasis (Neg), 97
patients (56.7%). Lymph nodes with Mac and Mic (n =
69, 40.4%) were considered ALNM-positive, and ITC
and negative cases were considered ALNM-negative
(n = 102, 59.6%).
Analysis of lymph node metastasis by PET/CT
The utility of the NT ratio in estimating ALNM was de-
termined based on the pathologic diagnosis. As shown
in Table 2, the tumor size, SUV-T, and SUV-LN were
significantly higher in the ALNM-positive cases than in
the ALNM-negative cases (tumor size: 23.9 mm and
Table 1 Patient characteristics (n = 171)
Number (%) Mean ± SD
Age (years) 59.2 ± 14.1














Verification of lymph node metastasis
Sentinel lymph node biopsy 101 59.1
Axillary lymph node dissection 70 40.9





ITC: Isolated tumor cells; ND: Not determined; SD: Standard division.
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SUV-LN: 2.289 and 0.841, P <0.01, respectively). The
NT ratio differed significantly between ALNM-positive
(0.5) and ALNM-negative (0.316) cases, respectively
(P = 0.041; Table 2).
The ALNM cases were then classified into two groups:
Mac (n = 55) and Mic (n = 14). The SUV-LN of the Mac
group (2.63) was significantly higher than that of theTable 2 Axillary lymph node evaluation by PET/CT
(mean ± SD)
Metastasis-positive Negative (+ITC)
(n = 69) (n = 102)
Age (years) 56.7 ± 13.6 61.7 ± 14.4
Tumor size (mm) 23.9 ± 12.6a 18.7 ± 10.4
SUV-LN 2.289 ± 2.425a 0.841 ± 0.288
SUV-T 6.165 ± 3.871a 3.954 ± 3.524
NT ratio 0.5 ± 0.707b 0.316 ± 0.209
Patients with metastasis-positive nodes (n = 69) were compared to those with
metastasis-negative nodes (n = 102). SD: Standard division. The node-negative
group included those diagnosed with isolated tumor cells (ITC).
aP <0.01.
bP = 0.041 vs. the node-negative group.Mic (0.935, P <0.01) and Neg groups (0.841, P <0.01).
The NT ratio of the Mac group (0.571) was also higher
than that of the Mic (0.227, P <0.01) and Neg (0.316,
P = 0.021) groups. Furthermore, the NT ratio of the Mac
group was higher than the NT ratio from both the Mic
and Neg (0.306, P = 0.0155) groups. However, there was
no statistical difference between the Mic and Neg groups
in the NT ratio (Table 3). Representative cases are
shown in Figure 1. These results suggest that the SUV-
LN and NT ratio are helpful in predicting Mac in axil-
lary lymph nodes.ROC curve analysis
A ROC curve analysis was performed to determine an
ideal cutoff value and associated sensitivity and specifi-
city for detecting Mac. An elevated SUVmax within the
axillary lymph node appeared to indicate metastasis;
therefore, the NT ratio and SUV-LN were compared by
ROC. The analysis revealed that the AUC for the NT ra-
tio (0.585) was inferior to that for the SUV-LN (0.779)
in detecting metastasis (P <0.01). Under these condi-
tions, the optimal cutoffs were 0.288 for the NT-ratio
and 1.00 for the SUV-LN. Using the AUC, Mac cases
were segregated from the remaining cases at an NT ratio
of 0.647 and an SUV-LN of 0.811 (P <0.01; Figure 2a).
However, in patients with an SUV-T <2.5, the NT ratio
was 0.798, which was higher than the NT ratio (0.178)
in patients with an SUV-T ≥2.5, despite the absence of
metastasis.
Accordingly, the NT ratio and SUV-LN AUC were
recalculated in patients with an SUV-T ≥2.5 (n = 118).
There was no statistical difference in the AUC be-
tween the NT ratio and SUV-LN groups (0.757 and
0.797, respectively, P = 0.55). The optimal cutoff values
were 0.199 for the NT ratio and 1.00 for the SUV-LN
(Figure 2b). These results indicate that the NT ratio may
be useful in detecting Mac, particularly in patients with
an SUV-T ≥2.5.Comparison of diagnostic performance
Not only common modalities such as US, CT, or MRI,
but also combined PET/CT have been suggested as use-
ful in detecting axillary lymph node metastasis based on
the SUV-LN. The characteristics of the NT ratio were
determined by comparing its diagnostic performance to
that of the SUV-LN. Using the set cutoff values (SUV-
max: 1.00; NT ratio: 0.288), the NT ratio and SUV-LN
sensitivities were 58.2% and 78.2%, their specificities
were 59.5% and 80.2%, and their accuracies were 59.1%
and 81.9%, respectively (Table 4). The NT ratio and
SUV-LN differed significantly (P = 0.039). However, in
the Neg group (n = 102), 71.2% of patients with a low
SUV-T (SUVmax <2.5; n = 42) showed a high NT ratio
Table 3 Comparison of axillary lymph node evaluation results according to the metastases size (mean ± SD)
Macrometastasis Micrometastasis Negative (+ITC) Micrometastasis + Negative
(n = 55) (n = 14) (n = 102) (n = 116)
Age (years) 56.6 ± 13.1 58.1 ± 17.6 61.7 ± 14.4 60.9 ± 14.5
Tumor size (mm) 24.5 ± 13.6a 20.9 ± 7.2 18.7 ± 10.4 19.0 ± 10.1
SUV-LN 2.63 ± 2.607b 0.935 ± 0.314 0.841 ± 0.288 0.856 ± 0.293
SUV-T 6.298 ± 4.122c 5.487 ± 2.223 3.954 ± 3.524 4.125 ± 3.427
NT ratio 0.571 ± 0.776d 0.227 ± 0.104 0.316 ± 0.209 0.306 ± 0.205
PET/CT parameters were compared between the four groups as follows: macrometastasis (Mac: n = 55), micrometastasis (Mic: n = 14), negative (Neg: n = 102), and
micrometastasis and negative (Mic + Neg: n = 116). avs. the Neg group (P <0.01); bvs. the Mic + Neg groups (P <0.01); cvs. the Neg group (P <0.01) or the Mic + Neg
group (P <0.01); dvs. the Mic group (P <0.01), Neg group (P = 0.021), or the Mic + Neg groups (P = 0.0155).
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a high SUV-T (SUVmax ≥2.5; n = 60).
Assuming that an NT ratio with a low SUV-T is un-
likely to be clinically significant, patients with a high
SUV-T (≥2.5; n = 118) were the focus of the remaining
analysis. Using the set cutoff values (SUV max: 1.00; NT
ratio: 0.199), the NT ratio and SUV-LN sensitivities were
68.9% and 75.6%, their specificities were 65.8% and
76.7%, and their accuracies were 66.9% and 76.3%, re-
spectively. There was no statistical difference between
the NT ratio and SUV-LN (P = 0.065). In addition, the
positive predictive values (PPV) were 55.4% and 65.4%,
and the negative predictive values (NPV) were 77.4%
and 83.6%, respectively, and did not differ significantly.
When the NT ratio and SUV-LN were used in combin-
ation, the sensitivity increased to 85.5% (for all cases)
and 84.4% (cases with SUV-T ≥2.5), respectively.
Discussion
For minimally invasive surgery of breast cancer, we
strongly believe in the importance of preoperatively
evaluating the axillary lymph node. We previously inves-
tigated the utility of navigation surgery based on com-
posite PET/CT and US images, specifically in cases ofFigure 1 Representative PET/CT images showing the NTcratio. (a) True
3.11, and a NT ratio of 0.381. (b) True negative case, 63-year-old woman w
positive case, 42-year-old woman with an SUV-T of 1.27, SUV-LN of 1.69, an
an SUV-T of 10.88, SUV-LN of 1.45, and a NT ratio of 0.132. The primary tum
arrow) showing the highest SUV-LN in the axillae are indicated.axillary neoplasia, and found that PET/CT is a valuable
tool for breast surgery [31]. The PET/CT-based NT ratio
was selected for preoperative quantitative evaluation be-
cause SUV measurement is simple and easy to perform.
Furthermore, this method can be used to evaluate both
the SLN and the non-SLN in the entire axillary space.
The technique was initially applied to non-small-cell
lung cancer (NSCLC) as a universal predictor of medias-
tinal node malignancy and showed a 0.56 cutoff value,
94% sensitivity, and 72% specificity [26]. These previous
data motivated us to use the NT ratio for axillary evalu-
ation in breast cancer patients. Recently, one report de-
scribed the utility of the NT ratio for predicting ALNM
in breast cancer patients [32]. The mean NT ratio was
0.3, and the cutoff value was 0.2; when the diagnostic
performance was assessed, the technique showed a
71.4% sensitivity and a 77.3% specificity. The AUC for
the NT ratio was 0.776 and was superior to the AUC for
the SUV-LN (0.705).
In the present study, the mean NT ratio for Mac
(0.571) was significantly higher than observed for Mic
(0.227) and node-negative lesions (0.316). Potentially,
the NT ratio may reflect the tumor burden, though the
number of Mic cases was small. Notably, 96% of patientspositive case, 57-year-old woman with an SUV-T of 8.69, SUV-LN of
ith an SUV-T of 9.63, SUV-LN of 1.07, and a NT ratio of 0.111. (c) False
d a NT ratio of 0.751. (d) False negative case, 62-year-old woman with
or (right panel, yellow arrow) and axillary lymph node (left panel, white
Figure 2 ROC curves for the NT ratio and SUV-LN. (a) Comparison of the AUCs between patients with Mac and those with Mic or negative
nodes (Mic + Neg) in the patient population. The AUCs for the NT ratio and SUV-LN were 0.647 and 0.811, respectively (P <0.01). (b) AUCs comparing
the Mac and Mic + Neg patients with an SUV-T ≥2.5 (n = 131). The AUCs for the NT ratio and SUV-LN were 0.757 and 0.797, respectively (P = 0.55,
not significant).
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(0.5-1.5) may interfere with evaluation. In 30 patients
with Mac and a low SUV-LN, 17 (57%) had a high NT
ratio (>0.288), suggesting that the NT-ratio may predict
patients with Mac. However, node-negative cases may
show false positive results, as shown in Figure 1. A total
42 of 46 (91%) node-negative cases with a low SUV-T
(<2.5) showed a seemingly high NT ratio (mean: 0.54,
range: 0.319-1.061). This discrepancy prompted a reex-
amination of the NT ratio accuracy in patients with a
high SUV-T (≥2.5; n = 118), and no statistical difference
was found between the AUCs of the NT-ratio (0.757)
and SUV-LN (0.797; Figure 2b). Under these conditions,Table 4 Comparison of diagnostic performance for
detecting macrometastasis
NT ratio SUV-LN Combination
All cases (n = 171) Cutoff 0.288 Cutoff : 1.00
Sensitivity 58.2 (46.4-69.2) 78.2 (67.3-86.7) 85.5 (74.7-92.8)
Specificity 59.5 (50.0-68.5) 80.2 (75.0-84.2) 50.0 (44.9-53.5)
PPV 40.5 (29.6-52.2) 65.2 (56.1-72.2) 44.8 ( 39.1-48.6)
NPV 75.0 (64.9-83.4) 88.3 (83.0-92.5) 87.9 (78.9-94.0)
Accuracy 59.1 (51.5-66.2) 81.9 (75–87.3) 61.4 (54.5-66.1)
SUV-T ≥ 2.5 (n = 118) Cutoff 0.199 Cutoff : 1.00
Sensitivity 68.9 (56.4-79.6) 75.6 (63.5-85.1) 84.4 (72.7-92.6)
Specificity 65.8 (68.1-72.4) 76.7 (69.3-82.6) 54.8 (47.5-59.8)
PPV 55.4 (45.3-64.0) 65.4 (55.0-73.7) 53.5 (46.1-58.7)
NPV 77.4 (68.4-85.2) 83.6 (75.5-90.0) 85.1 (73.8-92.9)
Accuracy 66.9 (57.4-75.1) 76.3 (67.1-83.5) 66.1 (57.7-72.3)
The diagnostic performance of the NT ratio, SUV-LN, and both techniques in
combination is indicated. Cutoff values for each modality were determined
based on the sensitivity and specificity. In the whole patient population (n = 171),
the cutoffs for the NT ratio and SUV-LN were 0.288 and 1.00, respectively; these
values were compared using the McNemar test (P = 0.013). In patients with an
SUV-T ≥2.5 (n = 118), the cutoffs for the NT ratio and SUV-LN were 0.199 and
1.00, respectively, with no significant difference noted.the sensitivities for Mac were 68.9% using the NT ratio
and 75.6% using the SUV-LN. However, combining these
methods increased the sensitivity to 84.4%. The NT ratio
appears to be particularly reliable in patients with an
SUV-T greater than 2.5. Our results suggest that the NT
ratio is one option for the preoperative quantification of
axillary lymph node metastasis. Combining the NT ratio
and the SUV-LN may be important for minimizing false
positive cases. However, tumors with a low SUV, in-
cluding low-grade malignancies or benign inflammatory
lesions, also warrant attention. Both morphological
evaluation by conventional modalities and assessment by
functional modalities such as the NT ratio and SUV-LN
using PET/CT are required to quantitatively diagnose the
axillary lymph node. Notably, all the data analyzed in this
study were obtained in patients prior to treatment.
Whether the NT ratio is efficacious in patients receiv-
ing chemo, endocrine, and molecular target therapies is
unclear. Reportedly, in tumors that were vulnerable to
chemotherapy, the SUV-T significantly decreased after
the second cycle of neoadjuvant chemotherapy, resulted
in low sensitivity (66.7% to 68%) and high specificity
(75% to 96.4%) for predicting the pathological complete
response (pCR) [33,34]. At present, there are no data on
lymph node assessment during neoadjuvant chemother-
apy. The therapeutic response at the metastatic site,
including lymph nodes, may differ from that for the pri-
mary tumor, which may make the NT ratio complex and
difficult to understand. When evaluating the effect of
neoadjuvant chemotherapy, changes in both the SUV-T
and SUV-LN should be considered.
Axillary evaluation is crucial for staging and thera-
peutic planning in patients with invasive breast cancer.
Although the current data was retrospectively analyzed
at a single institution, our findings suggest that both the
SUV-LN and the NT ratio obtained by PET/CT may
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A prospective large cohort study is recommended to val-
idate the NT ratio as a reliable predictor of Mac.
Conclusion
To determine the need for axillary lymph node dissec-
tion in patients with invasive breast cancer, we diag-
nosed the presence of axillary lymph node metastasis
using the NT ratio and SUV-LN obtained by PET/CT.
Both the NT ratio and SUV-LN were significantly higher
in patients with axillary macrometastasis than in those
with micrometastasis or no metastasis. Although the
utility of PET/CT in breast cancer remains unclear, the
NT ratio appears to be helpful in quantifying axillary
lymph node metastasis with similar utility to SUV-LN
and can assist in macrometastasis identification, particu-
larly in patients with an SUV-T greater than 2.5.
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